RHEUMATOID ARTHRITIS: NEW TREATMENT APPROACHES - A COMPARATIVE EVIDENCE REVIEW

dc.contributor.author	Akhmedov Khalmurad Sadullayevich, . Khojanazarov Ilkhom Eshkulovich,. Mullokulov Javohir Jamshid ugli,. Anorboyev Maruf Kholbuta ugli.
dc.date.accessioned	2025-11-13T15:08:29Z
dc.date.available	2025-11-13T15:08:29Z
dc.date.issued	2025
dc.identifier.citation	Toshkent	en_US
dc.identifier.uri	http://repo.tma.uz/xmlui/handle/1/2374
dc.description.abstract	Rheumatoid arthritis (RA) is a systemic autoimmune disease that has undergone a therapeutic revolution over the past two decades. Conventional synthetic DMARDs remain foundational, but the introduction of biologic and targeted synthetic DMARDs has transformed outcomes. This article reviews pivotal randomized controlled trials, comparative efficacy and safety data, and evolving treatment algorithms. Quantitative comparisons including absolute risk reduction (ARR), relative risk (RR), and number needed to treat (NNT) are provided for head-to-head studies, alongside safety analyses from ORAL Surveillance and regulatory guidance. A treat -to-target approach, precision medicine, and risk stratification remain essential for optimizing outcomes in 2025 and beyond.	en_US
dc.language.iso	en	en_US
dc.subject	Upadacitinib, bDMARDs, tofacitinib, baricitinib	en_US
dc.title	RHEUMATOID ARTHRITIS: NEW TREATMENT APPROACHES - A COMPARATIVE EVIDENCE REVIEW	en_US
dc.type	Article	en_US